What the trial was testing
The trial enrolled 130 patients with leukemia. The study was sponsored by Fred Hutchinson Cancer Center and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
95% of patients successfully engrafted their new cord blood cells, with 66% surviving three years.
Blood advances · 2020 · NCT00796068
These findings — that two-thirds of patients survived three years after transplant with this gentler regimen — were published in the Blood advances and represent the headline result of the study.
Researchers tracked outcomes across 130 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with leukemia, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This was a mid-stage study showing promising results with treosulfan-based conditioning before cord blood transplants. The treatment is not yet standard practice everywhere. If you're considering a cord blood transplant for leukemia or a related blood cancer, ask your transplant team whether treosulfan-based conditioning might be right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open leukemia trials
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse in patients diagnosed with leukemia, myelodysplastic syndromes (MDS), and related hematological conditions.
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676